Art. -Nr.: HY-N1570

Pterosin B

Kundenbewertung

Based on 1 Customer Validation

Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.98%
CAS. Nr.: 34175-96-7
Formel: C₁₄H₁₈O₂
Molecular Weight:218.30

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Pterosin B Chemical Structure

CAS. Nr.: 34175-96-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[2]

SIK3

Alle Salt-inducible Kinase (SIK) Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	50.1 μM Compound: 7	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28532669]

In Vitro

Pterosin B (300 μM; 5 days) reduces the amounts of Sik3, phosphorylated Hdac4, and phosphorylated Crtc1 in primary chondrocytes, similar to the effect of 4-OH tamoxifen^[2].
Pterosin B (10-50 μM; 48 h) inhibits Angiotensin II-induced cardiomyocyte hypertrophy in H9c2 cells, reducing hypertrophy-related gene expression, cell size, and protein synthesis^[3].
Pterosin B (1, 5 μM) promotes the phenotypic shift of lipopolysaccharide-induced BV-2 cells from M1 to M2, inhibits Klf5 expression, and attenuates Lipopolysaccharide-induced microglial glycolysis^[4].
Pterosin B (300 μM; 36 h) inhibits the SIK3 signaling pathway, suppressing the cytoplasmic localization of HDAC5 and CRTC2 in HEK293 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pterosin B (900 μM; intra-articular injection; 3 times a week; 8-12 weeks) protects mice from the development of osteoarthritis and reduces the expression of Col10 in the non-calcified zone of articular cartilage in wild-type mouse knee osteoarthritis models^[2].
Pterosin B (5-20 mg/kg; p.o.; 8 weeks) ameliorates cognitive deficits, reduces β-amyloid deposition, and inhibits excessive microglia activation in APP/PS1 mice^[4].
Pterosin B (0.1% in diet; p.o.; 1 month) lowers blood glucose levels and enhances insulin responses in db/db mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6NCrSlc male mice (male, 8-week-old or 13-week-old) with destabilized medial meniscus (DMM) surgery-induced osteoarthritis model^[2]
Dosage:

900 μM
Administration:

Intra-articular injection, three times a week, for 8 weeks (in 8-week-old mice) or 12 weeks (in 13-week-old mice)
Result:

Led to better OARSI scores in 8-week-old mice, indicating a protective effect against osteoarthritis development.
Reduced the Col10 expression activated by DMM in the non-calcified zone of articular cartilage.
Resulted in better OARSI scores and reduced Col10 expression in noncalcified areas of articular cartilage in 13-week-old mice.

Animal Model:

Male APP/PS1 mice (male, weight: 40 g, 6-month-old) with Alzheimer's disease model^[4]
Dosage:

5 mg/kg/day and 20 mg/kg/day (dissolved in 0.5% sodium carboxymethyl)
Administration:

Oral administration, for 8 weeks
Result:

Reduced escape latency and increased the number of platform crossings and target-zone duration.
Improved learning and memory.
Rescued the decline in spontaneous alternation rate.
Revealed a significant decrease in the Aβ_1-42-positive area.
Improved the number and arrangement of Nissl bodies in the hippocampal DG region.
Decreased the number of microglia in the cortex and CA1 region and inhibited the elevation of mRNA levels of inflammatory factors such as Tnfa, Il6, and Il1b in the hippocampus and serum.

Chemical Information

CAS. Nr. 34175-96-7
Appearance Solid
Molecular Weight 218.30
Formel C₁₄H₁₈O₂
Color White to light yellow
SMILES

O=C1[C@H](C)CC2=C1C(C)=C(CCO)C(C)=C2
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (1145.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.5809 mL

22.9043 mL

45.8085 mL

5 mM

0.9162 mL

4.5809 mL

9.1617 mL

10 mM

0.4581 mL

2.2904 mL

4.5809 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.75 mg/mL (12.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.75 mg/mL (12.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.75 mg/mL (12.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hannah R.Dexter, et al. A concise stereoselective synthesis of pterosin B. Tetrahedron Letters, Volume 59, Issue 49, 5 December 2018, Pages 4323-4325.

[2]. Yahara Y, et al. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice by inhibiting Sik3. Nat Commun. 2016 Mar 24;7:10959. [Content Brief]

[3]. Lee C Y, et al. Novel therapeutic effects of pterosin B on Ang II-induced cardiomyocyte hypertrophy. Molecules, 2020, 25(22): 5279.

[4]. Zhang Y, et al. Pterosin B improves cognitive dysfunction by promoting microglia M1/M2 polarization through inhibiting Klf5/Parp14 pathway. Phytomedicine. 2024 Dec;135:156152. [Content Brief]

[5]. Itoh Y. Pterosin B, ingredient in Pteridium aquilinum, regulates hepatic gluconeogenesis via SIK3-dependent and independent mechanisms. 2017.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.5809 mL	22.9043 mL	45.8085 mL	114.5213 mL
	5 mM	0.9162 mL	4.5809 mL	9.1617 mL	22.9043 mL
	10 mM	0.4581 mL	2.2904 mL	4.5809 mL	11.4521 mL
	15 mM	0.3054 mL	1.5270 mL	3.0539 mL	7.6348 mL
	20 mM	0.2290 mL	1.1452 mL	2.2904 mL	5.7261 mL
	25 mM	0.1832 mL	0.9162 mL	1.8323 mL	4.5809 mL
	30 mM	0.1527 mL	0.7635 mL	1.5270 mL	3.8174 mL
	40 mM	0.1145 mL	0.5726 mL	1.1452 mL	2.8630 mL
	50 mM	0.0916 mL	0.4581 mL	0.9162 mL	2.2904 mL
	60 mM	0.0763 mL	0.3817 mL	0.7635 mL	1.9087 mL
	80 mM	0.0573 mL	0.2863 mL	0.5726 mL	1.4315 mL
	100 mM	0.0458 mL	0.2290 mL	0.4581 mL	1.1452 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Pterosin B

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Neuronal Signaling Compound Library

Natural Product Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Glycolysis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Alle Salt-inducible Kinase (SIK) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Pterosin B Related Classifications

HY-N1570 Related Classifications